Sign in / Register 
Human IgG1 Kappa-AP
Cat. No.:
0151K-04
Human IgG1 Kappa-AP for use as a control in ELISA assays.
$154.00
| Isotype | Human IgG1κ |
|---|---|
| Source | Human myeloma serum |
| Conjugate | AP (Alkaline Phosphatase) |
| Buffer Formulation | 50 mM Tris/1 mM MgCl2/50% Glycerol containing < 0.1% sodium azide, pH 8.0 |
| Clonality | Purified from myeloma serum |
| Concentration | Lot specific |
| Volume | 1.0 mL |
| Recommended Storage | 2-8°C |
| Applications | Quality tested applications for relevant formats include - ELISA 1,2 FLISA Other referenced applications for relevant formats include - Flow Cytometry 8,9 Immunoprecipitation 3 In vitro control 4-6 In vivo control 1,7 Stimulation (Fc mediated) 10 Blocking 6 Surface Plasmon Resonance 1 |
| RRID Number | AB_2794080 |
Documentation
Certificate of Analysis Lookup
Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view
- 1. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-52. (ELISA, in vivo control, Surface plasmon resonance)
- 2. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun. 2009;33:270-4. (ELISA)
- 3. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210:241-56. (IP)
- 4. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66:869-80. (In vitro control)
- 5. Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-18. (In vitro control)
- 6. Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015;3:54. (In vitro control, Block)
- 7. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P, et al. Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. Cell Death Differ. 2015;22:1477-88. (In vivo control)
- 8. Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J Virol. 2015;89:512-22. (FC)
- 9. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54. (FC)
- 10. Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, et al. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. Sci Transl Med. 2016;8:365ra158. (Stim)
- 11. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82:5219-26. (Mass spectrometry)
See All References
Related Products
Check items to add to the cart or
